Gilead Sciences Aktie News

Gilead Sciences (GILD -2.85%) didn't have a bad first quarter, but investors didn't find it inspiring either. After publishing its earnings report after market close Thursday, the company saw its share price decline in excess of 2% the following day.

Gilead Sciences' Q1 2025 earnings report shows a slight decline in product sales, primarily due to lower Veklury sales and oncology inventory issues. The HIV division remains Gilead's strongest performer, with Biktarvi leading the charge, while oncology investments have yet to yield significant returns. Key upcoming milestones include the FDA decision on lenacapavir, a potential blockbuster HIV...

Pharmaceutical stocks are making headlines today, after two U.S.-based sector heavyweights stepped into the earnings confessional this morning and last night.

Gilead Sciences, Inc. (NASDAQ:GILD ) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ET Company Participants Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial Officer Dietmar Berger - Chief Medical Officer Andrew Dickinson - CFO Cindy Perettie - EVP, Kite Conference Call Participants Michael Yee - Jefferies Carter Gould - Cantor Fitzgerald...

Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. Gilead stock fell in late action.

Gilead Sciences on Thursday reported slightly higher-than-expected quarterly earnings on flat revenue, as higher sales of drugs for HIV and liver disease along with expense tightening offset lower cancer drug sales.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2025 results of operations. “Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management,” said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. “Our base business grew 4% year-over-year, pr...

Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's immunotherapy Keytruda significantly slowed disease progression in patients with an aggressive type of breast cancer.